MULTIPLE MYELOMA KNOWLEDGE CENTER

How is Empliciti administered?

Empliciti™ (elotuzumab, Bristol-Myers Squibb/AbbVie) is given as an intravenous (IV) infusion into a vein at a dose of 10 mg/kg of body weight. It is given along with Revlimid® (lenalidomide, Celgene) and dexamethasone once a week for the first two cycles and every 2 weeks thereafter.

Empliciti is given until disease progression or there is unacceptable toxicity.

Before receiving Empliciti, patients receive premedication with dexamethasone, antihistamines, and a fever-reducing agent (acetaminophen) to reduce the risk of infusion reactions, which can occur following administration of Empliciti.